Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Transgenomic Reports Revenue Rise, Surging Loss in Q1

NEW YORK, May 1 - Transgenomic today reported a 24 percent increase in revenue and a ballooning net loss as receding demand for its instruments contributed to a top-line shortfall.


Total revenue for the period ended March 31 came in at $9.8 million compared with $7.9 million one year ago. CEO Greg Duman said that 8 percent of its instrument sales this quarter came from commercial customers compared with between 25 and 35 percent the company usually draws.


R&D spending remained more or less unchanged at $2.7 million, Transgenomic said.


Still, net loss for the quarter ballooned to $3.4 million, or $.14 per share, compared with $1.1 million, or $.05 per share, year over year, the company said.


Transgenomic said it had roughly $35 million in cash and cash equivalents as of March 31.


Click here for more information.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.